Results 211 to 220 of about 18,568,522 (331)

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

open access: yesActa Ophthalmologica, EarlyView.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler   +17 more
wiley   +1 more source

Outcome and safety of multiple photodynamic therapy sessions in chronic central serous chorioretinopathy

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose This study evaluates the effectiveness and safety of multiple PDT sessions for cases of persistent and recurrent subretinal fluid (SRF) in chronic central serous chorioretinopathy (CSC). Methods This multicentre, retrospective cohort study included patients aged ≥18 years with chronic CSC who received at least two sessions of PDT at ...
Jennifer M. Chang‐Wolf   +7 more
wiley   +1 more source

Refinement of the MYP3 locus on human chromosome 12 in a German family with Mendelian autosomal dominant high-grade myopia by SNP array mapping

open access: bronze, 2008
Frank Jacobi   +7 more
openalex   +2 more sources

Visual acuity, amblyopia and refractive error in preterm children with and without retinopathy of prematurity – Results from the Gutenberg Prematurity Study Young (GPSY)

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose This study aims to assess visual outcomes in children born preterm, stratified by gestational age, hypo‐ and hypertrophy, and the presence of retinopathy of prematurity (ROP) and its treatment. Methods This is a prospective observational cohort study (n = 949, 1889 eyes) assessing visual acuity, amblyopia, refractive error, and lens ...
Achim Fieß   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy